Cargando…

The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda

BACKGROUND: The global increase in the burden of multidrug-resistant tuberculosis (MDR-TB) underscores an urgent need for data on factors involved in generation and spread of TB drug resistance. We performed molecular analyses on a representative sample of Mycobacterium tuberculosis (MTB) isolates....

Descripción completa

Detalles Bibliográficos
Autores principales: Ezati, Nicholas, Lukoye, Deus, Wampande, Eddie M, Musisi, Kenneth, Kasule, George W, Cobelens, Frank GJ, Kateete, David P, Joloba, Moses L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367914/
https://www.ncbi.nlm.nih.gov/pubmed/25523472
http://dx.doi.org/10.1186/s12879-014-0703-0
_version_ 1782362565649629184
author Ezati, Nicholas
Lukoye, Deus
Wampande, Eddie M
Musisi, Kenneth
Kasule, George W
Cobelens, Frank GJ
Kateete, David P
Joloba, Moses L
author_facet Ezati, Nicholas
Lukoye, Deus
Wampande, Eddie M
Musisi, Kenneth
Kasule, George W
Cobelens, Frank GJ
Kateete, David P
Joloba, Moses L
author_sort Ezati, Nicholas
collection PubMed
description BACKGROUND: The global increase in the burden of multidrug-resistant tuberculosis (MDR-TB) underscores an urgent need for data on factors involved in generation and spread of TB drug resistance. We performed molecular analyses on a representative sample of Mycobacterium tuberculosis (MTB) isolates. Basing on findings of the molecular epidemiological study in Kampala, we hypothesized that the predominant MTB strain lineage in Uganda is negatively associated with anti-TB drug resistance and we set out to test this hypothesis. METHODS: We extracted DNA from mycobacterial isolates collected from smear-positive TB patients in the national TB drug resistance survey and carried out IS6110-PCR. To identify MTB lineages/sub lineages RT-PCR SNP was performed using specific primers and hybridization probes and the ‘melting curve’ analysis was done to distinguish the Uganda II family from other MTB families. The primary outcome was the distribution of the Uganda II family and its associations with anti-TB drug resistance and HIV infection. RESULTS: Out of the 1537 patients enrolled, MTB isolates for 1001 patients were available for SNP analysis for identification of Uganda II family, of which 973 (97%) had conclusive RT-PCR results. Of these 422 (43.4%) were of the Uganda II family, mostly distributed in the south west zone (55.0%; OR = 4.6 for comparison with other zones; 95% CI 2.83-7.57; p < 0.001) but occurred in each of the other seven geographic zones at varying levels. Compared to the Uganda II family, other genotypes as a group were more likely to be resistant to any anti-TB drug (OR(adj) =2.9; 95% CI 1.63-5.06; p = 0.001) or MDR (OR(adj) 4.9; 95% CI, 1.15-20.60; p = 0.032), even after adjusting for geographic zone, patient category, sex, residence and HIV status. It was commonest in the 25–34 year age group 159/330 (48.2%). No association was observed between Uganda II family and HIV infection. CONCLUSION: The Uganda II family is a major cause of morbidity due to TB in all NTLP zones in Uganda. It is less likely to be resistant to anti-TB drugs than other MTB strain lineages. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0703-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4367914
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43679142015-03-21 The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda Ezati, Nicholas Lukoye, Deus Wampande, Eddie M Musisi, Kenneth Kasule, George W Cobelens, Frank GJ Kateete, David P Joloba, Moses L BMC Infect Dis Research Article BACKGROUND: The global increase in the burden of multidrug-resistant tuberculosis (MDR-TB) underscores an urgent need for data on factors involved in generation and spread of TB drug resistance. We performed molecular analyses on a representative sample of Mycobacterium tuberculosis (MTB) isolates. Basing on findings of the molecular epidemiological study in Kampala, we hypothesized that the predominant MTB strain lineage in Uganda is negatively associated with anti-TB drug resistance and we set out to test this hypothesis. METHODS: We extracted DNA from mycobacterial isolates collected from smear-positive TB patients in the national TB drug resistance survey and carried out IS6110-PCR. To identify MTB lineages/sub lineages RT-PCR SNP was performed using specific primers and hybridization probes and the ‘melting curve’ analysis was done to distinguish the Uganda II family from other MTB families. The primary outcome was the distribution of the Uganda II family and its associations with anti-TB drug resistance and HIV infection. RESULTS: Out of the 1537 patients enrolled, MTB isolates for 1001 patients were available for SNP analysis for identification of Uganda II family, of which 973 (97%) had conclusive RT-PCR results. Of these 422 (43.4%) were of the Uganda II family, mostly distributed in the south west zone (55.0%; OR = 4.6 for comparison with other zones; 95% CI 2.83-7.57; p < 0.001) but occurred in each of the other seven geographic zones at varying levels. Compared to the Uganda II family, other genotypes as a group were more likely to be resistant to any anti-TB drug (OR(adj) =2.9; 95% CI 1.63-5.06; p = 0.001) or MDR (OR(adj) 4.9; 95% CI, 1.15-20.60; p = 0.032), even after adjusting for geographic zone, patient category, sex, residence and HIV status. It was commonest in the 25–34 year age group 159/330 (48.2%). No association was observed between Uganda II family and HIV infection. CONCLUSION: The Uganda II family is a major cause of morbidity due to TB in all NTLP zones in Uganda. It is less likely to be resistant to anti-TB drugs than other MTB strain lineages. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0703-0) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-19 /pmc/articles/PMC4367914/ /pubmed/25523472 http://dx.doi.org/10.1186/s12879-014-0703-0 Text en © Ezati et al.; licensee BioMed Central. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ezati, Nicholas
Lukoye, Deus
Wampande, Eddie M
Musisi, Kenneth
Kasule, George W
Cobelens, Frank GJ
Kateete, David P
Joloba, Moses L
The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda
title The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda
title_full The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda
title_fullStr The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda
title_full_unstemmed The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda
title_short The Mycobacterium tuberculosisUganda II family and resistance to first-line anti-tuberculosis drugs in Uganda
title_sort mycobacterium tuberculosisuganda ii family and resistance to first-line anti-tuberculosis drugs in uganda
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367914/
https://www.ncbi.nlm.nih.gov/pubmed/25523472
http://dx.doi.org/10.1186/s12879-014-0703-0
work_keys_str_mv AT ezatinicholas themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT lukoyedeus themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT wampandeeddiem themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT musisikenneth themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT kasulegeorgew themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT cobelensfrankgj themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT kateetedavidp themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT jolobamosesl themycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT ezatinicholas mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT lukoyedeus mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT wampandeeddiem mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT musisikenneth mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT kasulegeorgew mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT cobelensfrankgj mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT kateetedavidp mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda
AT jolobamosesl mycobacteriumtuberculosisugandaiifamilyandresistancetofirstlineantituberculosisdrugsinuganda